Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Inv. presentation
Acq. announced
CC transcript

MADRIGAL PHARMACEUTICALS, INC. (MDGL) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 SC 13G/A JANUS HENDERSON GROUP PLC reports a 15.4% stake in MADRIGAL PHARMACEUTICALS, INC.
10/05/2023 SC 13D/A BAKER BROS. ADVISORS LP reports a 10% stake in Madrigal Pharmaceuticals, Inc.
10/02/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement",
"FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] Warrant No. Original Issue Date: [ ], 2023 MADRIGAL PHARMACEUTICALS, INC.",
"Hogan Lovells US LLP"
10/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/28/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2023 SC 13D/A BAKER BROS. ADVISORS LP reports a 8.4% stake in Madrigal Pharmaceuticals, Inc.
08/08/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/08/2023 8-K Quarterly results
Docs: "Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results"
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/17/2023 8-K Quarterly results
07/12/2023 144 Form 144 - Report of proposed sale of securities:
06/30/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis"
05/09/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/09/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 1 to Sales Agreement, by and between Madrigal Pharmaceuticals, Inc. and Cowen and Company, LLC",
"Legal Opinion of Hogan Lovells US LLP"
05/09/2023 8-K Quarterly results
Docs: "Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results"
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/21/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results"
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A BAKER BROS. ADVISORS LP reports a 9% stake in MADRIGAL PHARMACEUTICALS, INC.
02/14/2023 SC 13G/A ARMISTICE CAPITAL, LLC reports a 1.2% stake in MADRIGAL PHARMACEUTICALS, INC.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 SC 13G/A Deep Track Capital, LP reports a 0% stake in Madrigal Pharmaceuticals, Inc.
02/09/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Tranche 2 Warrant Agreement, by and among Madrigal Pharmaceuticals, Inc. and Hercules Capital, Inc. and affiliates",
"Loan and Security Agreement, as amended by the First Amendment to Loan and Security Agreement, by and among Madrigal Pharmaceuticals, Inc., Canticle Pharmaceuticals, Inc., the several banks and other financial institutions or entities from time to time party thereto and Hercules Capital, Inc"
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/10/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
12/23/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/23/2022 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulat...
Docs: "Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock",
"Legal Opinion of Hogan Lovells US LLP",
"Securities Purchase Agreement, by and among Madrigal Pharmaceuticals, Inc. and the institutional investors listed on the signature pages thereto",
"Amendment No. 2, to Securities Purchase Agreement, by and among Madrigal Pharmaceuticals, Inc. and the investors listed on the signature pages thereto",
"Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program"
12/19/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy